Market Place
Sourcing Support
Indaptus Therapeutics CMO Roger Waltzman to Moderate CMO360 Summit
25 Mar 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Reports Successful Immune Activation in Dec
20 Mar 2025 //
GLOBENEWSWIRE
Tribe Public Webinar With Indaptus Therapeutics
12 Mar 2025 //
GLOBENEWSWIRE
Indaptus Expands Patent Portfolio In China, Japan, And Israel
04 Mar 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics’ CSO Dr. Michael Newman to Present at 10th
25 Feb 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Receives in Canada Approval for Decoy20 Trial
05 Feb 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Announce 2.25M Private Placement Under Nasdaq
13 Jan 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Provides Year-End Review & Outlook for 2025
08 Jan 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Announces $2.135M Registered Offering
22 Nov 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics Publishes Immunotherapy Research in Immunology
11 Nov 2024 //
GLOBENEWSWIRE
Indaptus Presents Safety Data from Decoy20 Phase 1 at SITC 2024
07 Nov 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics to Present at Investor Conferences
23 Oct 2024 //
GLOBENEWSWIRE
Indaptus Signs Clinical Supply Agreement With BeiGene
22 Oct 2024 //
GLOBENEWSWIRE
Indaptus Initiates Unrestricted Enrollment Of Decoy20 Weekly Dosing
15 Oct 2024 //
GLOBENEWSWIRE
Indaptus Founder To Speak On Cancer Immunotherapy Webinar
10 Oct 2024 //
GLOBENEWSWIRE
Indaptus To Participate In Maxim Healthcare Virtual Summit
08 Oct 2024 //
GLOBENEWSWIRE
Indaptus Reports New Safety Data For Decoy20 Program
05 Sep 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Indaptus Reports Q2 2024 Results And Provides Corporate Update
12 Aug 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics Announces $3.0M Registered Direct Offering And Placement
07 Aug 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics to Present +ve Data on Lead Product Candidate, Decoy20
11 Jun 2024 //
GLOBENEWSWIRE
Indaptus: Positive Decoy20 Data At Immuno-Oncology Conference
04 Jun 2024 //
GLOBENEWSWIRE
Indaptus` Decoy20 Shows Positive Phase 1 Data
03 Jun 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Indaptus Pulse-Prime Data For Decoy20 At ASCO From Phase 1
29 May 2024 //
GLOBENEWSWIRE
Indaptus Doses First Patient With Decoy20 Cancer Therapy
22 May 2024 //
GLOBENEWSWIRE
Indaptus Q1 2024 Results, Corporate Update
08 May 2024 //
GLOBENEWSWIRE
Indaptus Positive Cancer Mechanism Data At AACR
11 Apr 2024 //
GLOBENEWSWIRE
Indaptus to Present at the MedInvest Biotech and Pharma Investor Conference
28 Mar 2024 //
GLOBENEWSWIRE
Indaptus Previews +ve Mechanism of Action Data to be Presented at the A ACR
25 Mar 2024 //
GLOBENEWSWIRE
Indaptus to Participate in Tribe Public Webinar On March 20, 2024
18 Mar 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
Indaptus Announces Positive Results from Second Cohort of Phase 1 Trial
04 Mar 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
15 Feb 2024 //
GLOBENEWSWIRE
Indaptus Expands Digital Presence with Launch of Social Media Channels
08 Feb 2024 //
GLOBENEWSWIRE
European Patent Office Approves Key Patent for Indaptus` Platform Technology
04 Jan 2024 //
GLOBENEWSWIRE
Indaptus Decoy20 Demonstrated a Broad Immune Response of Fifty Cytokines
06 Nov 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Indaptus to Present PD Immune and PK Results from Phase 1 Study of Decoy20
31 Oct 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics to Present at the LD Micro Main Event XVI
27 Sep 2023 //
GLOBENEWSWIRE
Indaptus Doses First Patient in Single Dose Ranging Study of Decoy20
19 Sep 2023 //
GLOBENEWSWIRE
Indaptus to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Indaptus Announces Opening of Next Cohort in Study of Decoy20
10 Aug 2023 //
GLOBENEWSWIRE
Indaptus Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer
07 Aug 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics to Participate in the Maxim Group Virtual Conference
15 Jun 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023
31 May 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Following Granting of Indian Patent, Indaptus Patent Protection 32 Countries
09 May 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics Chief Scientific Officer Michael Newman
01 May 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023
20 Apr 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy
19 Apr 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform
17 Apr 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics to Present at the Investor Summit Conference
22 Mar 2023 //
GLOBENEWSWIRE
Indaptus Reports Fourth Quarter and Year-End 2022 Financial Results
17 Mar 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform
15 Mar 2023 //
GLOBENEWSWIRE
Indaptus Activates Emory Winship Cancer Institute as Trial Site in INDP-D101
13 Mar 2023 //
GLOBENEWSWIRE
Indaptus Doses First Subject in Phase 1 Open Label Trial of Decoy20
07 Mar 2023 //
GLOBENEWSWIRE
Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to Board of Directors
14 Feb 2023 //
GLOBENEWSWIRE
